EMA (EU)
EVENT
Regulatory Perspectives on Herbal Medicinal / Botanical Drug Product Development: Joint FDA / EMA Workshop
Published: 9/25/2026Detected: 9/18/2026
Summary preview
Joint FDA/EMA workshop on herbal medicinal and botanical drug product development, which may shape how sponsors design CMC, clinical evidence, and safety documentation for complex botanical constituents.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountmanufacturing
quality
clinical
safety
labeling
#herbal medicinal products
#botanical drug development
#EMA
#FDA
#CMC
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026